The 30-day risks of hospitalization were 17.5%, 15.9%, and 14.4% for COVID, influenza, and RSV, respectively, during the 2022 ...

More than 86,000 recorded cases of respiratory syncytial virus in 2024 were in children younger than four years old.

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

U.S. surges of COVID-19, influenza, respiratory syncytial virus (RSV) and norovirus have collectively been dubbed a ...

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

Wales is past the peak of its flu season according to public health bosses. Cases of flu have caused chaos in Wales' ...

UPMC saw an increase in RSV cases in its health system, including in Lancaster County, a spokesperson said Jan. 7, especially ...

RSV is usually contagious for three to eight days. A patient also may be contagious a day or two before experiencing symptoms ...

Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.

Tis the season—for the flu, COVID, stomach bugs, and other nasty viruses that can knock us down for several days, causing ...